Literature DB >> 23102711

Delivery strategies to optimize resource utilization and performance status for patients with advanced life-limiting illness: results from the "palliative care trial" [ISRCTN 81117481].

Amy P Abernethy1, David C Currow, Tania Shelby-James, Debra Rowett, Frank May, Gregory P Samsa, Roger Hunt, Helena Williams, Adrian Esterman, Paddy A Phillips.   

Abstract

CONTEXT: Evidence-based approaches are needed to improve the delivery of specialized palliative care.
OBJECTIVES: The aim of this trial was to improve on current models of service provision.
METHODS: This 2×2×2 factorial cluster randomized controlled trial was conducted at an Australian community-based palliative care service, allowing three simultaneous comparative effectiveness studies. Participating patients were newly referred adults, experiencing pain, and who were expected to live >48 hours. Patients enrolled with their general practitioners (GPs) and were randomized three times: 1) individualized interdisciplinary case conference including their GP vs. control, 2) educational outreach visiting for GPs about pain management vs. control, and 3) structured educational visiting for patients/caregivers about pain management vs. control. The control condition was current palliative care. Outcomes included Australia-modified Karnofsky Performance Status (AKPS) and pain from 60 days after randomization and hospitalizations.
RESULTS: There were 461 participants: mean age 71 years, 50% male, 91% with cancer, median survival 179 days, and median baseline AKPS 60. Only 47% of individuals randomized to the case conferencing intervention received it; based on a priori-defined analyses, 32% of participants were included in final analyses. Case conferencing reduced hospitalizations by 26% (least squares means hospitalizations per patient: case conference 1.26 [SE 0.10] vs. control 1.70 [SE 0.13], P=0.0069) and better maintained performance status (AKPS case conferences 57.3 [SE 1.5] vs. control 51.7 [SE 2.3], P=0.0368). Among patients with declining function (AKPS <70), case conferencing and patient/caregiver education better maintained performance status (AKPS case conferences 55.0 [SE 2.1] vs. control 46.5 [SE 2.9], P=0.0143; patient/caregiver education 54.7 [SE 2.8] vs. control 46.8 [SE 2.1], P=0.0206). Pain was unchanged. GP education did not change outcomes.
CONCLUSION: A single case conference added to current specialized community-based palliative care reduced hospitalizations and better maintained performance status. Comparatively, patient/caregiver education was less effective; GP education was not effective.
Copyright © 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23102711     DOI: 10.1016/j.jpainsymman.2012.02.024

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  27 in total

1.  A Pilot Trial of Early Specialty Palliative Care for Patients with Advanced Pancreatic Cancer: Challenges Encountered and Lessons Learned.

Authors:  Yael Schenker; Nathan Bahary; Rene Claxton; Julie Childers; Edward Chu; Dio Kavalieratos; Linda King; Barry Lembersky; Greer Tiver; Robert M Arnold
Journal:  J Palliat Med       Date:  2017-08-03       Impact factor: 2.947

2.  The role of palliative care in population management and accountable care organizations.

Authors:  Grant Smith; Rachelle Bernacki; Susan D Block
Journal:  J Palliat Med       Date:  2015-02-27       Impact factor: 2.947

3.  The effect of palliative care on patient functioning.

Authors:  Donald H Taylor; Janet Bull; Xiaoyin Zhong; Greg Samsa; Amy P Abernethy
Journal:  J Palliat Med       Date:  2013-09-10       Impact factor: 2.947

4.  Indicators of integration of oncology and palliative care programs: an international consensus.

Authors:  D Hui; S Bansal; F Strasser; T Morita; A Caraceni; M Davis; N Cherny; S Kaasa; D Currow; A Abernethy; C Nekolaichuk; E Bruera
Journal:  Ann Oncol       Date:  2015-06-18       Impact factor: 32.976

Review 5.  Multicomponent Palliative Care Interventions in Advanced Chronic Diseases: A Systematic Review.

Authors:  Veerawat Phongtankuel; Lauren Meador; Ronald D Adelman; Jordan Roberts; Charles R Henderson; Sonal S Mehta; Tessa Del Carmen; M C Reid
Journal:  Am J Hosp Palliat Care       Date:  2016-11-10       Impact factor: 2.500

Review 6.  Implementing Evidence-Based Palliative Care Programs and Policy for Cancer Patients: Epidemiologic and Policy Implications of the 2016 American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Sarina R Isenberg; Rebecca A Aslakson; Thomas J Smith
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

Review 7.  Populations and Interventions for Palliative and End-of-Life Care: A Systematic Review.

Authors:  Adam E Singer; Joy R Goebel; Yan S Kim; Sydney M Dy; Sangeeta C Ahluwalia; Megan Clifford; Elizabeth Dzeng; Claire E O'Hanlon; Aneesa Motala; Anne M Walling; Jaime Goldberg; Daniella Meeker; Claudia Ochotorena; Roberta Shanman; Mike Cui; Karl A Lorenz
Journal:  J Palliat Med       Date:  2016-08-17       Impact factor: 2.947

Review 8.  Interventions for interpersonal communication about end of life care between health practitioners and affected people.

Authors:  Rebecca E Ryan; Michael Connolly; Natalie K Bradford; Simon Henderson; Anthony Herbert; Lina Schonfeld; Jeanine Young; Josephine I Bothroyd; Amanda Henderson
Journal:  Cochrane Database Syst Rev       Date:  2022-07-08

9.  Overcoming recruitment challenges in palliative care clinical trials.

Authors:  Thomas W LeBlanc; Jordan E Lodato; David C Currow; Amy P Abernethy
Journal:  J Oncol Pract       Date:  2013-10-15       Impact factor: 3.840

10.  Academic detailing of general practitioners by a respiratory physician for diagnosis and management of refractory breathlessness: a randomised pilot study.

Authors:  Aileen Collier; Debra Rowett; Peter Allcroft; Aine Greene; David C Currow
Journal:  BMC Health Serv Res       Date:  2015-05-09       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.